title: Intracellular and extracellular remodeling effectively prevents human CD8(+)cytotoxic T lymphocyte-mediated xenocytotoxicity by coexpression of membrane-bound human FasL and pig c-FLIP(L) in pig endothelial cells.
abstract: Human CD8(+) cytotoxic T lymphocyte (CTL)-mediated cytotoxicity, which participates in xenograft rejection, is mediated mainly by the Fas/FasL apoptotic pathway. We previously developed methods to inhibit human CTL xenocytotoxicity by extracellular remodeling using overexpression of membrane-bound human FasL on pig xenograft cells, and by intracellular blockade of death receptor-mediated apoptotic signals, such as the Fas/FasL pathway using the pig c-FLIP(L) molecule. To investigate the cooperative effects of both membrane-bound FasL and pig c-FLIP(L), we cotransfected both genes into pig endothelial cells (PEC). The double remodeling with these molecules effectively prevented CD8(+) CTL killing. Although double transfectants and single high transfectants of either membrane-bound FasL or c-FLIP(L) gene displayed similar inhibition of CTL cytotoxicity, the expression levels of these 2 molecules in double transfectants were almost half the expression levels of single transfectants. Furthermore, to show in vivo prolongation of xenograft survival, we transplanted PEC transfectants under the rat kidney capsule. Prolonged survival was displayed by PEC double transfectant xenografts whereas those from either parental PEC or MOCK (vehicle control) were completely rejected by day 5 posttransplantation. These data suggested that intracellular and extracellular remodeling by coexpression of membrane-bound FasL and pig c-FLIP(L) in xenograft cells may prevent an innate cellular response to xenografts. The gene compatibility of these molecules to generate transgenic pigs may be sufficient to create a window of opportunity to facilitate long-term xenograft survival.
authors.affiliation: Osaka University Graduate School of Medicine, Osaka, Japan. mtanemura@gesurg.med.osakau.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Tanemura
authors.forename: A
authors.initials: A
authors.lastname: Saga
authors.forename: K
authors.initials: K
authors.lastname: Kawamoto
authors.forename: T
authors.initials: T
authors.lastname: Machida
authors.forename: T
authors.initials: T
authors.lastname: Deguchi
authors.forename: T
authors.initials: T
authors.lastname: Nishida
authors.forename: Y
authors.initials: Y
authors.lastname: Sawa
authors.forename: Y
authors.initials: Y
authors.lastname: Doki
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Ito
mesh_terms: D000818:Animals; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000235:genetics*; D018929:Cell Culture Techniques; D002470:Cell Survival / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D018076:DNA, Complementary / Q000235:genetics; D053222:Fas Ligand Protein / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D010957:Plasmids / Q000235:genetics; D013552:Swine; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*; D014162:Transfection; D014183:Transplantation, Heterologous / Q000276:immunology*
chemical_list: D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D018076:DNA, Complementary; C505661:FASLG protein, human; D053222:Fas Ligand Protein